News

Under the terms of agreement, Kyoto University and Takeda will work closely to discover new drug targets and biomarkers for obesity and schizophrenia. The two parties will conduct

Based on the analysis of 552 PFS events in 711 patients, the study achieved its primary endpoint with a statistically significant 28% reduction in the risk of progression

The tie up allows Ironwood Pharma to develop new peptides and treatments for therapeutic areas with unmet medical needs. During the collaboration period, Protagonist will use its disulfide

Amgen‘s 100,000sqft manufacturing facility houses process development labs with pilot plant and currently employs 360 employees. Amgen has acquired Fremont facility through its 2006 acquisition of Abgenix. Boehringer

Extedo is a solutions and services provider in the field of eRegulatory Affairs. Extedo claims that its eCTDmanager Suite is an easy-to-use electronic management solution for building, viewing,

Harbor BioSciences retains the rights to these products in US and rest of the world, and CIPI will provide the company all the pre-clinical and clinical data it

Microbix Biosystems is a biotechnology company commercializing novel technologies for influenza vaccine manufacturing and livestock semen sexing, in addition to a core business of virology products. Earlier, Baron

CureFAKtor Pharma is intending to conduct a Phase I clinical study of CFAK-C4 in combination with gemcitabine chemotherapy in 2012. CureFAKtor Pharma president and CEO Shep Wild said

Mylan Pharmaceuticals, a subsidiary of Mylan Inc, has claimed that its Acarbose tablets is the generic version of Bayer’s Precose tablets, a treatment to be used with diet